A Breakthrough Platform That Goes Where Others Can’t
Safe, targeted gene therapy — delivered directly to the brain.
Our Core Technologies
Most therapies can’t effectively reach the brain. Our platform combines precision gene editing, RNA therapeutics, and an intranasal delivery system to bypass the brain’s protective blood barriers.
CRISPR-based Prime Editing
Repairs DNA mutations with unmatched accuracy — without cutting. Designed to minimize off-target effects for safer gene therapy.
RNA Formulations
Enables precise and intended gene expression with targeted control to treat complex neurological conditions like Alzheimer’s and Parkinson’s.
Intranasal Nano-Delivery
Delivers prophylactic and therapeutic agents directly to targeted brain cells—bypassing invasive injections and minimizing systemic side effects and off-target risks.
Inside the Breakthrough:
How Our Platform Solves What Others Can’t
Precise Gene Editing
CRISPR-based prime editing system targets genetic mutations with high precision by introducing biologics known as the prime editors, to the intended site enabling safer and more efficient genome modification.
Science That Reaches the Brain
Our patented intranasal nano-delivery system bypasses the blood-brain barrier to deliver treatment directly—no injections required.
From Lab Bench to Bedside
We work with globally recognized scientists to turn clinical research into therapies that transform patient outcomes.
A New Standard in Precision Gene Therapy
NanoMedX’s advanced nanocarrier achieves over 98.67% transfection efficiency in preclinical murine models—far surpassing the 5–30% seen with traditional lipid nanoparticles (LNPs).
Transfection success rate using NanoMedX's nano-delivery system
LNP transfection rate in the same model
Partner With Us to Bring Groundbreaking Therapies to Life
Join us in transforming neurological care through co-development, licensing, or investment. Let’s solve the unsolved—together.
